What is the difference between MASLD, NAFLD, MASH, and NASH?

MASLD and NAFLD are the same condition under two names, with MASLD the term adopted in 2023 to describe fat in the liver alongside a metabolic driver. MASH (formerly NASH) is the more advanced form, where the liver becomes inflamed and injured on top of being fatty, which is the step that lays down scar tissue. If your records use the older NAFLD or NASH, they are describing the same disease.

What is the difference between MASLD, NAFLD, MASH, and NASH?

MASLD and NAFLD are the same condition under two names, with MASLD the term adopted in 2023 to describe fat in the liver alongside a metabolic driver. MASH (formerly NASH) is the more advanced form, where the liver becomes inflamed and injured on top of being fatty, which is the step that lays down scar tissue. If your records use the older NAFLD or NASH, they are describing the same disease.

Fatty Liver (MASLD): Is It Serious and Can It Be Reversed? | Philadelphia

TL;DR30-second take

Fatty liver, now called MASLD (metabolic dysfunction-associated steatotic liver disease), means excess fat has built up in the liver alongside a metabolic driver like insulin resistance. It affects roughly 1 in 4 adults worldwide. In its early stages it is reversible: losing 7 to 10% of body weight can clear the fat and even reverse early scarring. Fishtown Medicine stages it without a biopsy using the FIB-4 score and a FibroScan, treats the insulin resistance underneath it, and tracks the numbers back down.

TL;DR: Fatty liver, now named MASLD (metabolic dysfunction-associated steatotic liver disease), means fat has built up in the liver alongside a metabolic driver like insulin resistance. It affects about 1 in 4 adults worldwide, usually causes no symptoms, and is often waved off after a routine lab result. It should not be. In its early stages it is reversible, and it is also a marker that the same process straining your liver is straining your heart. Losing 7 to 10% of body weight can clear the fat and reverse early scarring. At Fishtown Medicine we stage it without a biopsy, treat the insulin resistance underneath it, and follow the numbers back down.

If a routine blood test came back with slightly high liver enzymes, or an ultrasound for something else mentioned a "fatty liver," and you were told it was common and nothing to worry about, I want to give you a fuller picture. Fatty liver is common, that part is true. It is also the most frequent chronic liver condition in the world, it is usually the liver's version of a metabolic warning light, and in the stage most people are found in, it can be turned around. Being told it is common is not the same as being told what it means or what to do about it. This page covers both.

What is MASLD (metabolic dysfunction-associated steatotic liver disease)?

MASLD is a buildup of excess fat in the liver in a person who also has a metabolic risk factor, such as insulin resistance, prediabetes or type 2 diabetes, excess weight around the middle, high triglycerides, low HDL, or high blood pressure. The fat itself is not the whole story. The diagnosis is made when liver fat and at least one of those cardiometabolic drivers show up together, because it is that pairing, fat plus metabolic strain, that carries the risk.¹

Most people with MASLD feel nothing. There are usually no symptoms, which is why it is so often found by accident, on a lab panel that shows a mildly high ALT or AST, or on an ultrasound or CT ordered for another reason. Some people notice fatigue or a vague fullness under the right ribs, but the absence of symptoms is not reassurance. It is the reason the condition tends to sit unaddressed for years.

The concern lies less in the fat itself and more in where the process can go if the metabolic driver keeps pushing. In a subset of people, plain fatty liver progresses to MASH (metabolic dysfunction-associated steatohepatitis), where the liver becomes inflamed and injured on top of being fatty, and it is inflammation over time that lays down scar tissue, or fibrosis. The goal of finding MASLD early is to treat the driver while the liver is still fatty but unscarred, because that is the stage that reverses.

Why did the name change from fatty liver and NAFLD to MASLD?

The name changed in 2023 because the old label, NAFLD (non-alcoholic fatty liver disease), defined the condition by what it was not rather than what it is. A group of liver societies replaced it with MASLD to name the driver itself, metabolic dysfunction, and to drop wording that many patients found stigmatizing.¹ The inflamed, injured form once called NASH is now MASH. If your chart or an older article says NAFLD or NASH, it is describing the same condition under the previous name.

This is more than relabeling. Defining the condition by its metabolic root points the treatment where it belongs. A fatty liver is rarely a standalone liver problem. It usually travels with insulin resistance, and it moves in the same direction as the rest of your metabolic health, which is why treating the whole system, rather than the liver in isolation, is what works.

Is a fatty liver serious, or is it harmless?

A fatty liver is not harmless, but its most likely danger is not the one people expect. For most people with MASLD, the leading cause of death is cardiovascular disease, not liver failure.² The fatty liver is a visible sign that insulin resistance and metabolic dysfunction are active, and that same process is steadily raising the risk of heart attack and stroke. So a fatty liver is worth taking seriously less because your liver is likely to fail and more because it is telling you something about your arteries.

The liver risk is present for a smaller group. A share of people with MASLD progress to MASH, and a share of those go on to develop advanced fibrosis or cirrhosis over years. The single strongest predictor of long-term liver outcomes is the amount of fibrosis (scarring) already present, which is why staging matters more than simply confirming that fat is there.² Two people can both have a "fatty liver" on an ultrasound, and one has no scarring while the other has meaningful fibrosis. They need very different plans, and only staging tells them apart.

How is MASLD diagnosed and staged without a biopsy?

MASLD is diagnosed by finding liver fat on imaging in someone with a metabolic risk factor, and it is staged for fibrosis with non-invasive tools rather than a biopsy in almost all cases. The two that do most of the work are the FIB-4 score and a FibroScan.

FIB-4 score. This is a simple, validated calculation from your age and three numbers already on standard labs: AST, ALT, and platelet count, and it estimates the likelihood of advanced fibrosis.³ In fatty liver, a FIB-4 below 1.3 makes advanced scarring unlikely and above 2.67 makes it much more likely, with the middle range calling for a better look. It costs nothing extra because the inputs are already drawn.
FibroScan (vibration-controlled transient elastography). A painless scan, done at a specialist office, that measures how stiff the liver is (a stand-in for scarring) and how much fat it holds. It is the most useful single non-invasive test for staging and for following change over time.
Liver enzymes are a weak screen on their own. ALT and AST can be normal even when a fatty liver is present, so normal enzymes do not rule it out. They point toward it without confirming it.

A liver biopsy, once the default, is now reserved for the minority of cases where the non-invasive picture is unclear or another liver condition is in question. When a biopsy or any procedure is needed, we bring in highly qualified hepatology and GI specialists who are in network for you, rather than doing it in house.

Can a fatty liver be reversed?

Yes. In its early stages a fatty liver is reversible, and the most reliable lever is weight loss. Losing about 5% of body weight tends to reduce liver fat, and losing 7 to 10% has been shown to resolve steatohepatitis and, in a meaningful share of people, reverse early fibrosis.⁴ The liver is one of the more forgiving organs when the metabolic pressure comes off it. Take away the driver and it can clear.

The word "reverse" earns some honesty here. Clearing the fat and calming the inflammation is very achievable at the stage most people are found. Reversing established scarring is harder and less certain the further it has gone, which is the whole argument for finding and treating MASLD early rather than watching it. The work that reverses it is the work that fixes the metabolism underneath: enough protein and resistance training to build and hold muscle (muscle is where you dispose of glucose), cutting added sugar, fructose, and alcohol, sleep, and steady loss of visceral fat. There is no supplement or single food that does this. The liver follows the whole system.

What about the newer medications like resmetirom and GLP-1s?

The medications mark meaningful progress, and they work best as accelerants on top of the metabolic work rather than as replacements for it. Resmetirom (Rezdiffra), the first drug approved specifically for MASH with fibrosis, improved both inflammation and scarring versus placebo in its phase 3 trial.⁵ GLP-1 medications such as semaglutide, used for weight and glucose, also improve MASH by taking pressure off the whole metabolic system, and have shown resolution of steatohepatitis in trials.⁶

What I want you to hold onto is that these tools lower the load on the liver by fixing the driver, weight and insulin resistance, which is the same target lifestyle change aims at. They earn their place when the metabolic work needs help or when fibrosis is already present and time matters. They do not replace the foundation, and used without it, the gains tend not to hold.

Can you have a fatty liver if you are not overweight?

Yes. Roughly 1 in 10 to 1 in 5 people with MASLD are lean, sometimes called lean MASLD, and it is more common in people of South Asian and East Asian descent, who tend to carry fat viscerally rather than under the skin. Genetic variants such as PNPLA3 also raise the risk of fatty liver in some people regardless of their weight.² A normal BMI does not clear you. Someone can be a normal weight on the scale, carry fat around the organs, run high triglycerides and high fasting insulin, and have a fatty liver. This is one reason we look at fasting insulin, triglycerides, and body composition rather than trusting weight alone, and it is a pattern we see often in Philadelphia's South Asian community.

How Fishtown Medicine approaches fatty liver in Philadelphia

We treat a fatty liver as a metabolic diagnosis rather than a footnote on a lab report. The first job is to stage it with care: a FIB-4 from labs, a FibroScan when it adds something, fasting insulin and a full lipid picture to size up the driver, and a look for anything else that could be raising your enzymes. The second job is to treat what is under it, because the liver fat is downstream of insulin resistance, and fixing the metabolism is what clears the liver and lowers the heart risk that travels with it.

The reason we can manage this at a level above standard primary care is that we do the work in depth and we do not do it alone. For anything that calls for a procedure, a biopsy or a specialized scan, we refer to highly qualified hepatology and GI specialists who are in network for you. And when a case is complex or the picture is mixed, we actively reach out to a network of specialists to compare notes across cases, so you often get an expert opinion folded into your plan without a separate extra visit. Whether you are in Fishtown or Rittenhouse, or coming across the bridge from Cherry Hill or Moorestown, the aim is the same: name it early, treat the driver, and watch the numbers come back down.

Guidance from the Clinic

"When someone comes in worried about a fatty liver, I try to reframe it early. The fatty liver is not the enemy, it is the messenger. It is showing us that insulin resistance is active, and that gives us a target we can move. We are not going to shame anyone for a number on a scan. We are going to figure out what is driving it and take the pressure off, and the liver, more often than not, does the rest."

Key Takeaways

Fatty liver (MASLD) is the most common chronic liver condition in the world, affecting about 1 in 4 adults, and it usually causes no symptoms.
Its biggest danger for most people is cardiovascular, not liver failure - it is a visible sign that insulin resistance is active and straining the heart too.
It is staged without a biopsy using a FIB-4 score from routine labs and a painless FibroScan; normal liver enzymes do not rule it out.
Early fatty liver is reversible - losing 7 to 10% of body weight can clear the fat and reverse early scarring by fixing the insulin resistance underneath it.
A normal weight does not clear you - lean MASLD is well documented, which is why we look at fasting insulin, triglycerides, and body composition rather than weight alone.
Fishtown Medicine stages and treats MASLD in Philadelphia and South Jersey, referring to in-network hepatology for procedures and complex cases.

Metabolic Health and Insulin Resistance - the driver underneath a fatty liver
Prediabetes: The Reversal Window - catching insulin resistance before it moves
ApoB and Heart Health - the cardiovascular risk that travels with a fatty liver
Advanced Lipid Testing in Philadelphia - triglycerides, HDL, and the fuller metabolic picture
Continuous Glucose Monitoring - seeing the glucose swings that drive liver fat

Scientific References

Rinella ME, Lazarus JV, Ratziu V, et al. "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Hepatology. 2023;78(6):1966-1986.
Targher G, Byrne CD, Tilg H. "MASLD: a systemic metabolic disorder with cardiovascular and malignant complications." Gut. 2024;73(4):691-702.
Sterling RK, Lissen E, Clumeck N, et al. "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection." Hepatology. 2006;43(6):1317-1325.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. "Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis." Gastroenterology. 2015;149(2):367-378.
Harrison SA, Bedossa P, Guy CD, et al. "A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis." New England Journal of Medicine. 2024;390(6):497-509.
Newsome PN, Buchholtz K, Cusi K, et al. "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis." New England Journal of Medicine. 2021;384(12):1113-1124.

Fishtown Medicine | Metabolism

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

A fatty liver is a warning sign worth acting on, though the most likely danger for most people is cardiovascular, not liver failure. MASLD signals that insulin resistance and metabolic dysfunction are active, and that same process raises the risk of heart attack and stroke, which is the leading cause of death in people with a fatty liver. A smaller group progresses to liver inflammation and scarring over years. Both risks are reasons to treat it early rather than watch it.

Early fatty liver is reversible, and the strongest lever is weight loss. Losing about 5% of body weight reduces liver fat, and 7 to 10% can resolve inflammation and reverse early scarring. Reversing established scarring is harder the further it has gone, which is why finding and treating it early matters. The work that reverses it is the work that fixes insulin resistance: protein and resistance training, cutting sugar and alcohol, sleep, and steady loss of visceral fat.

Added sugar (particularly fructose from sweetened drinks), refined carbohydrates, and alcohol are the main dietary drivers, because the liver turns excess fructose and alcohol into fat directly. Ultra-processed foods that spike insulin add to the load. The most effective changes are cutting sugar-sweetened drinks, reducing alcohol, and building meals around protein and whole foods, alongside enough resistance training to hold muscle.

Deep-Dive Questions

A fatty liver is a heart risk more than a liver risk because it is a visible marker of the same insulin resistance and metabolic dysfunction that drive atherosclerosis. The liver fat, the high triglycerides, the low HDL, the high blood pressure, and the artery damage all share one root: a metabolic system under strain. For most people with MASLD, that shared root expresses itself as cardiovascular disease long before the liver ever fails, which is why a fatty liver on a scan should prompt a look at ApoB, Lp(a), and the rest of the cardiovascular picture alongside the liver.

The FIB-4 score estimates how likely you are to have advanced scarring in the liver, calculated from your age and three routine numbers: AST, ALT, and platelet count. A result below 1.3 makes advanced fibrosis unlikely and is reassuring, above 2.67 raises concern and calls for specialist evaluation, and the middle range is indeterminate and usually leads to a FibroScan for a clearer answer. It is a triage tool rather than a final diagnosis, and its value is that it costs nothing extra because the inputs are already on your labs.

Building muscle helps a fatty liver because skeletal muscle is the body's largest site for disposing of glucose, and more muscle means more capacity to pull sugar out of the blood without the insulin surges that drive fat into the liver. Resistance training also improves insulin sensitivity directly, independent of weight loss. This is why a plan built only around eating less, without protein and strength work to protect and build muscle, tends to underperform: it can lower the number on the scale while leaving the metabolic driver of the liver fat in place.

Yes, on both counts. Liver enzymes such as ALT and AST are frequently normal in MASLD, so normal enzymes do not rule it out, and imaging can show fat when the blood work looks normal. Likewise, lean MASLD occurs in people with a normal BMI, more often in those of South Asian and East Asian descent, who carry fat viscerally and run high fasting insulin and triglycerides despite a normal weight. This is why fasting insulin, triglycerides, and body composition tell a truer story than weight or a basic enzyme panel alone.

Ready when you are